Premium
TAMOXIFEN VERSUS CHEMOTHERAPY AS ADJUVANT TREATMENT IN STAGE III BREAST CANCER
Author(s) -
Alagaratnam Thevakaruna T.,
Wong John
Publication year - 1986
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1986.tb01817.x
Subject(s) - medicine , tamoxifen , cyclophosphamide , breast cancer , oncology , fluorouracil , chemotherapy , doxorubicin , adjuvant , stage (stratigraphy) , randomized controlled trial , adjuvant chemotherapy , cancer , paleontology , biology
A randomized prospective trial was conducted to compare Tamoxifen and combination chemotherapy (5‐fluorouracil, doxorubicin and cyclophosphamide) as adjuvant treatment for patients with locally advanced (Stage III) breast cancer. At the end of 5 years, no significant difference could be found in the disease‐free period for both groups.